Haleon plc 6-K, filed Apr 3, 2025
Haleon plc (HLN)
6-K
2025-04-03
For: 2025-04-03
View Original
Added on
April 05, 2026
About this 6-K
Haleon plc filed this 6-K on April 3, 2025.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April
2025
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
03
April 2025 - “Transaction in Own Shares”
|
99.1
Haleon plc: Transaction
in own shares
03 April 2025: Haleon
plc (the "Company" or "Haleon") today announces the
purchase of the following number of ordinary shares of £0.01
each in the Company (the "Shares") for
cancellation under
its share buyback programme announced on 28 March
2025 (the
"Buyback Programme").
|
Date of
purchase:
|
02
April 2025
|
|
Number
of Shares purchased:
|
826,862
|
|
Highest
price paid per Share (p):
|
389.20
|
|
Lowest
price paid per Share (p):
|
385.60
|
|
Volume
weighted average price paid per Share (p):
|
387.11
|
Following the settlement of the above, the Company's registered
share capital is
9,036,501,550 ordinary shares of £0.01 each, of
which 4,080,205 are held as treasury shares. Therefore,
the number of ordinary shares with voting rights is 9,032,421,345
and this
figure may be used by shareholders to determine if they are
required to notify their interest, or a change to their interest,
in Haleon under the FCA's Disclosure Guidance and Transparency
Rules.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014
as it applies in the UK (the Market Abuse Regulation), a
full breakdown of the individual trades is available at the link
below:
This announcement does not constitute, or form part of, an offer or
any solicitation of an offer for securities in any
jurisdiction.
This announcement and individual trade breakdown will also be
available on the Company's website at: www.haleon.com/investors.
|
Enquiries
|
|
||
|
Investors
|
Media
|
||
|
Jo
Russell
|
+44 7787 392441
|
Zoë Bird
|
+44
7736 746167
|
|
Rakesh
Patel
|
+44
7552 484646
|
Victoria
Durman
|
+44 7894 505730
|
|
Emma
White
|
+44
7823 523562
|
|
|
|
Email: investor-relations@haleon.com
|
Email: corporate.media@haleon.com
|
||
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health,
with a purpose to deliver better everyday health with humanity.
Haleon's product portfolio spans five major categories - Oral
Health, Pain Relief, Respiratory Health, Digestive Health and
Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren,
Theraflu, Otrivin, Polident, parodontax and Centrum - are built on
trusted science, innovation and deep human
understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date: April 03,
2025
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|